ArticleJHLT open2026
CT-based cannula position predicts neurological risk in patients with HeartMate 3 LVAD.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Despite the HeartMate 3 (HM3) improved hemocompatibility, adverse neurological events (ANE) remain a major concern, and limited data exists on the combined effect of inflow and outflow cannula positioning on ANE risk. Methods: This single-center study included 103 HM3 recipients who underwent contrast-enhanced cardiac CT between 2016 and 2024. We measured inflow angle, inflow depth, distance to the anterior wall, and outflow angle. Optimal cutoffs were identified using ROC analysis, with associations with ANE evaluated by Kaplan-Meier and Cox regression. Results: Among the 103 patients, 25 (24%) experienced ANE over a median follow-up of 3.1 years. The ANE group had significantly shallower inflow depth (13.0 vs. 16.7 mm; p = 0.011) and a shorter distance to the anterior wall (13.0 vs. 16.7 mm; p = 0.006), along with a non-significant trend toward a larger outflow angle (56.3° vs. 51.7°; p = 0.175) and a more inferior inflow angle (-3.3°; p = 0.294). In multivariable Cox regression, inflow angle ≤ -4.1° (HR 4.34; 95% CI: 1.42-13.23), inflow depth ≤ 14.5 mm (HR 5.03; 95% CI: 1.76-14.37), and outflow angle > 42.7° (HR 5.52; 95% CI: 1.19-25.72) were independently associated with ANE. A greater number of cannula-related anatomical risk factors was significantly associated with worse 5-year ANE-free survival (p = 0.0004). Conclusions: Shallower inflow depth, inflow angle closer to inferior wall, and larger outflow angle, are significantly associated with ANE in HM3 patients. Optimizing cannula orientation during implantation may help mitigate stroke risk in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.